Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy

Figures & data

Figure 1. Determination of FA-PEG-DSPE to CUR-NLCs ratio.

Table 1. Quantification of decoration ratios of FA to NLCs’ surface.

Formulations (L/C)	Decoration efficiency (%)	Decoration ratio (μg/mg)
2/10	99.8 ± 1.06	19.4 ± 0.3
3/10	98.6 ± 1.32	28.7 ± 0.4
4/10	93.2 ± 1.21	36.2 ± 0.3
5/10	78.3 ± 2.23	38.0 ± 0.5
6/10	66.5 ± 2.61	38.7 ± 0.5

L/C represents ratios of FA-PEG-DSPE to CUR-NLCs (w/w).

Figure 2. TEM images of FA-CUR-NLCs and CUR-NLCs.

Table 2. Characterization of different NLCs.

Formulations	Blank NLCs	CUR-NLCs	FA-CUR-NLCs
Particle size (nm)	86.2 ± 2.3	92.6 ± 3.2	126.8 ± 3.4
Size distribution (PDI)	0.09 ± 0.02	0.15 ± 0.03	0.16 ± 0.04
Zeta potential (mV)	+18.5 ± 1.3	+ 14.9 ± 1.7	+ 12.6 ± 1.8
EE (%)	N/A	83.6 ± 2.7	82.7 ± 2.9
DL (%)	N/A	8.3 ± 1.2	5.1 ± 0.8

Figure 3. The in vitro release profiles of FA-CUR-NLCs and CUR-NLCs.

Table 3. IC₅₀ of formulations to MCF-7 cells.

Formulations	CUR solution	CUR-NLCs	FA-CUR-NLCs
IC50 (μmol/l)	18.23 ± 2.56	6.16 ± 0.67	1.75 ± 0.29

Figure 4. The tumor growth curves of different formulations treated in vivo.

Figure 5. The body weight change curves of different groups.